Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.35 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869377 | 0.82 | PIM1 (0.39) | PIM1KDM1AMEN1TDP2CFTR | |
| SCHEMBL30869597 | 0.79 | PIM1 (0.50) | PIM1KDM1AMEN1TDP2CFTR | |
| SCHEMBL30869543 | 0.77 | EGFR (0.41) | — | |
| SCHEMBL30869811 | 0.73 | PIM1 (0.41) | PIM1KDM1AMEN1TDP2CFTR | |
| SCHEMBL30869737 | 0.72 | KDM1A (0.51) | PIM1KDM1AMEN1TDP2CFTR | |
| SCHEMBL30869423 | 0.70 | PIM1 (0.40) | PIM1MEN1TDP2CFTRCASP6 | |
| SCHEMBL30869458 | 0.70 | TSHR (0.56) | PIM1MEN1TDP2CFTRCASP6 | |
| SCHEMBL30869712 | 0.67 | PIM1 (0.41) | PIM1MEN1TDP2CFTRCASP6 | |
| SCHEMBL32685459 | 0.67 | AHR (0.47) | PIM1MEN1KMT2ADRD2HTR2A | |
| SCHEMBL29645038 | 0.66 | DRD3 (0.44) | GRM2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | PIM1 4177/4885KDM1A 3264/4885MEN1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.